CL2016002607A1 - Procedimiento para preparar una preparación farmacéutica de acetato de glatiramer y manitol en un contenedor adecuado que comprende las etapas de obtener una solución acuosa de acetato de glatiramer y manitol, filtración de la solución entre 0 y 17,5 grado celsius y llenado del contenedor. pct - Google Patents
Procedimiento para preparar una preparación farmacéutica de acetato de glatiramer y manitol en un contenedor adecuado que comprende las etapas de obtener una solución acuosa de acetato de glatiramer y manitol, filtración de la solución entre 0 y 17,5 grado celsius y llenado del contenedor. pctInfo
- Publication number
- CL2016002607A1 CL2016002607A1 CL2016002607A CL2016002607A CL2016002607A1 CL 2016002607 A1 CL2016002607 A1 CL 2016002607A1 CL 2016002607 A CL2016002607 A CL 2016002607A CL 2016002607 A CL2016002607 A CL 2016002607A CL 2016002607 A1 CL2016002607 A1 CL 2016002607A1
- Authority
- CL
- Chile
- Prior art keywords
- mannitol
- glatiramer acetate
- container
- solution
- procedure
- Prior art date
Links
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 title abstract 4
- 108010072051 Glatiramer Acetate Proteins 0.000 title abstract 4
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 title abstract 4
- 229960003776 glatiramer acetate Drugs 0.000 title abstract 4
- 238000001914 filtration Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 title abstract 2
- 229930195725 Mannitol Natural products 0.000 title 2
- 235000010355 mannitol Nutrition 0.000 title 2
- 239000000594 mannitol Substances 0.000 title 2
- 239000007864 aqueous solution Substances 0.000 title 1
- 239000000243 solution Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/608,126 US9155775B1 (en) | 2015-01-28 | 2015-01-28 | Process for manufacturing glatiramer acetate product |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2016002607A1 true CL2016002607A1 (es) | 2017-05-26 |
Family
ID=54199060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2016002607A CL2016002607A1 (es) | 2015-01-28 | 2016-10-13 | Procedimiento para preparar una preparación farmacéutica de acetato de glatiramer y manitol en un contenedor adecuado que comprende las etapas de obtener una solución acuosa de acetato de glatiramer y manitol, filtración de la solución entre 0 y 17,5 grado celsius y llenado del contenedor. pct |
Country Status (30)
| Country | Link |
|---|---|
| US (6) | US9155775B1 (enExample) |
| EP (3) | EP3113785A4 (enExample) |
| JP (2) | JP2018503627A (enExample) |
| KR (2) | KR101737295B1 (enExample) |
| CN (1) | CN107530394B (enExample) |
| AR (1) | AR102096A1 (enExample) |
| AU (4) | AU2015380381B2 (enExample) |
| BR (1) | BR112016023736A2 (enExample) |
| CA (2) | CA2945537C (enExample) |
| CL (1) | CL2016002607A1 (enExample) |
| CY (1) | CY1118826T1 (enExample) |
| DK (1) | DK3050556T3 (enExample) |
| EA (3) | EA028484B1 (enExample) |
| ES (1) | ES2584190T3 (enExample) |
| HR (1) | HRP20170625T1 (enExample) |
| HU (1) | HUE034059T2 (enExample) |
| IL (3) | IL247851A0 (enExample) |
| LT (1) | LT3050556T (enExample) |
| ME (1) | ME02721B (enExample) |
| MX (1) | MX352734B (enExample) |
| PE (1) | PE20170296A1 (enExample) |
| PL (1) | PL3050556T3 (enExample) |
| PT (1) | PT3050556T (enExample) |
| RS (1) | RS55959B1 (enExample) |
| RU (1) | RU2669769C2 (enExample) |
| SI (1) | SI3050556T1 (enExample) |
| SM (1) | SMT201700227T1 (enExample) |
| UA (1) | UA116060C2 (enExample) |
| WO (1) | WO2016122722A1 (enExample) |
| ZA (1) | ZA201606903B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| CA2814500A1 (en) | 2010-10-11 | 2012-04-19 | Teva Pharmaceutical Industries Ltd | Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate |
| HK1200274A1 (en) | 2011-10-10 | 2015-08-07 | Teva Pharmaceutical Industries Ltd. | Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate |
| HK1213830A1 (zh) | 2012-10-10 | 2016-07-15 | Teva Pharmaceutical Industries Ltd. | 用於预测醋酸格拉替雷临床反应的生物标志物 |
| UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
| CN107550853B (zh) * | 2016-06-30 | 2020-06-12 | 深圳翰宇药业股份有限公司 | 一种醋酸格拉替雷注射液的制备方法 |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| CN109982712A (zh) | 2016-08-31 | 2019-07-05 | Mapi医药公司 | 包含醋酸格拉替雷的储库系统 |
| WO2018106945A1 (en) | 2016-12-07 | 2018-06-14 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
| CN110382052A (zh) | 2017-03-26 | 2019-10-25 | Mapi医药公司 | 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统 |
| WO2019005072A1 (en) | 2017-06-29 | 2019-01-03 | Regeneron Pharmaceuticals Inc. | Devices and methods for overfilling drug containers |
| US20200306516A1 (en) | 2017-08-14 | 2020-10-01 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with glatiramer or a pharmaceutically acceptable salt thereof |
| CN112933210A (zh) * | 2019-12-11 | 2021-06-11 | 深圳翰宇药业股份有限公司 | 一种西曲瑞克冻干药物组合物的制备方法 |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL36670A (en) | 1971-04-21 | 1974-09-10 | Sela M | Therapeutic basic copolymers of amino acids |
| FR2459619B1 (fr) | 1979-06-26 | 1983-07-29 | Agronomique Inst Nat Rech | Procede pour l'obtention a partir de lactoserum, d'un produit enrichi en alpha-lactalbumine et applications dudit procede |
| US4350156A (en) | 1980-05-29 | 1982-09-21 | Japan Foundation For Artificial Organs | Method and apparatus for on-line filtration removal of macromolecules from a physiological fluid |
| US4455256A (en) | 1981-05-05 | 1984-06-19 | The Regents Of The University Of California | Bone morphogenetic protein |
| US5599309A (en) | 1993-03-24 | 1997-02-04 | Owen Mumford Limited | Injection devices |
| IL113812A (en) | 1994-05-24 | 2000-06-29 | Yeda Res & Dev | Copolymer-1 pharmaceutical compositions containing it and its use |
| US5631347A (en) | 1995-06-07 | 1997-05-20 | Eli Lilly And Company | Reducing gelation of a fatty acid-acylated protein |
| DE19543737A1 (de) | 1995-11-24 | 1997-05-28 | Hoechst Ag | Verfahren zur Ultrafiltration von Peptide oder Proteine enthaltender biologischer Matrices |
| US6214791B1 (en) | 1997-01-10 | 2001-04-10 | Yeda Research And Development Co. Ltd. | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 |
| IL119989A0 (en) | 1997-01-10 | 1997-04-15 | Yeda Res & Dev | Pharmaceutical compositions for oral treatment of multiple sclerosis |
| ES2527760T3 (es) | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
| IL141021A0 (en) | 1998-07-23 | 2002-02-10 | Yeda Res & Dev | Treatment of autoimmune conditions with copolymer 1 and related copolymers |
| WO2000005249A2 (en) | 1998-07-23 | 2000-02-03 | The President And Fellows Of Harvard College | Synthetic peptides and methods of use for autoimmune disease therapies |
| US6800287B2 (en) | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| DK2239269T3 (da) | 1998-09-25 | 2013-04-29 | Yeda Res & Dev | Anvendelse af peptider afledt af copolymer-1 som molekylvægtsmarkører |
| US6514938B1 (en) | 1998-09-25 | 2003-02-04 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| WO2000020010A1 (en) | 1998-10-02 | 2000-04-13 | Yeda Research And Development Co., Ltd. | Alternate day administration of copolymer 1 for treating autoimmune diseases |
| AU775073C (en) | 1998-11-12 | 2007-05-03 | Yeda Research And Development Co. Ltd. | Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating GVHD and HVGD |
| IL150895A0 (en) | 2000-02-18 | 2003-02-12 | Teva Pharma | Oral, nasal and pulmonary formulations of copolymer-1 |
| US7022663B2 (en) | 2000-02-18 | 2006-04-04 | Yeda Research And Development Co., Ltd. | Oral, nasal and pulmonary dosage formulations of copolymer 1 |
| US20020077278A1 (en) | 2000-06-05 | 2002-06-20 | Yong V. Wee | Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| HUP0302333A3 (en) | 2000-06-05 | 2005-07-28 | Teva Pharma | The use of glatiramer acetate (copolymer 1) for the preparation of pharmaceutical compositions available in the treatment of central nervous system disorders |
| WO2002076503A1 (en) | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
| DE10158009A1 (de) * | 2001-11-21 | 2003-05-28 | Begerow E Gmbh & Co | Verfahren zur Reduzierung der Gesamtkeimzahl in wäßrigen Dispersionen |
| US7429374B2 (en) | 2001-12-04 | 2008-09-30 | Teva Pharmaceutical Industries, Ltd. | Process for the measurement of the potency of glatiramer acetate |
| CA2411786C (en) | 2002-11-13 | 2009-01-27 | Brantford Chemicals Inc. | A process for the preparation of polypeptides from n-carboxyanhydrides of amino acids |
| US7777006B2 (en) | 2002-12-31 | 2010-08-17 | Csl Behring L.L.C. | Method for purification of alpha-1-antitrypsin |
| RU2339397C2 (ru) | 2003-01-21 | 2008-11-27 | Йеда Рисерч Энд Дивелопмент Ко.Лтд. | Сор1 для лечения воспалительных заболеваний кишечника |
| US20070037740A1 (en) | 2003-03-04 | 2007-02-15 | Irit Pinchasi | Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis |
| WO2004103297A2 (en) | 2003-05-14 | 2004-12-02 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis |
| BRPI0412735A (pt) | 2003-07-18 | 2006-09-26 | Baxter Int | métodos para a fabricação, uso e composição de partìculas esféricas pequenas preparadas mediante a separação de fase controlada |
| JP2007509981A (ja) | 2003-10-31 | 2007-04-19 | テバ ファーマシューティカル インダストリーズ リミティド | 薬物デリバリー用ナノ粒子 |
| WO2005063800A2 (en) | 2003-12-31 | 2005-07-14 | F. Hoffmann-La Roche Ag | Peptide synthesis using decanting filter |
| EP1778286A4 (en) | 2004-03-03 | 2009-04-08 | Teva Pharma | COMBINATION THERAPY WITH ACETATE OF GLATIRAMER AND RILUZOLE |
| US20060194725A1 (en) | 2004-05-07 | 2006-08-31 | James Rasmussen | Methods of treating disease with random copolymers |
| US7655221B2 (en) | 2004-05-07 | 2010-02-02 | Peptimmune, Inc. | Methods of treating disease with random copolymers |
| EP1796710A4 (en) | 2004-09-02 | 2010-05-26 | Teva Pharma | THERAPY COMBINED WITH GLATIRAMER ACETATE AND N-ACETYLCYSTEINE TO TREAT MULTIPLE SCLEROSIS |
| HRP20160455T1 (hr) | 2004-09-09 | 2016-07-15 | Yeda Research And Development Co., Ltd. | Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene |
| ZA200702591B (en) | 2004-09-09 | 2009-03-25 | Teva Pharma | Process for preparation of mixtures of polypeptides using purified hydrobromic acid |
| AR052321A1 (es) | 2004-10-29 | 2007-03-14 | Sandoz Ag | Procesos para la preparacion de un polipeptido |
| JP2008528589A (ja) | 2005-02-02 | 2008-07-31 | テバ ファーマシューティカル インダストリーズ リミティド | 水素化分解を用いてポリペプチド混合物を作成する方法 |
| US20100167983A1 (en) | 2007-10-22 | 2010-07-01 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis |
| WO2006089164A1 (en) | 2005-02-17 | 2006-08-24 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis |
| CA2606194A1 (en) | 2005-04-25 | 2006-11-02 | Yeda Research And Development Company | Markers associated with the therapeutic efficacy of glatiramer acetate |
| US20070059798A1 (en) | 2005-09-09 | 2007-03-15 | Alexander Gad | Polypeptides useful for molecular weight determinations |
| WO2007081975A2 (en) | 2006-01-11 | 2007-07-19 | Teva Pharmaceutical Industries, Ltd. | Method of treating multiple sclerosis |
| US20080118553A1 (en) | 2006-06-12 | 2008-05-22 | Anton Frenkel | Tannate salt form of polypeptide mixtures, their preparation and use |
| JP2009542864A (ja) | 2006-07-05 | 2009-12-03 | モメンタ ファーマシューティカルズ インコーポレイテッド | コポリマー１の調製のための改良法 |
| CN100569282C (zh) | 2006-10-13 | 2009-12-16 | 俞嘉林 | 注射用骨肽冻干剂及其制备方法 |
| US8753833B2 (en) | 2007-06-21 | 2014-06-17 | Momenta Pharmaceuticals, Inc. | Copolymer assay |
| US8993722B2 (en) | 2007-07-31 | 2015-03-31 | Natco Pharma Limited | Process for the preparation glatiramer acetate (copolymer-1) |
| CA2702437C (en) | 2007-11-28 | 2013-06-25 | Teva Pharmaceutical Industries Ltd. | Method of delaying the onset of clinically definite multiple sclerosis |
| US8030297B2 (en) | 2008-05-14 | 2011-10-04 | Otonomy, Inc. | Controlled release corticosteroid compositions and methods for the treatment of OTIC disorders |
| US8323685B2 (en) | 2008-08-20 | 2012-12-04 | Baxter International Inc. | Methods of processing compositions containing microparticles |
| CA2697570C (en) | 2009-07-15 | 2011-11-01 | Teva Pharmaceutical Industries, Ltd. | Reduced volume formulation of glatiramer acetate and methods of administration |
| US8920373B2 (en) | 2009-07-15 | 2014-12-30 | Teva Pharmaceutical Industries, Ltd. | Reduced volume formulation of glatiramer acetate and methods of administration |
| NZ598661A (en) * | 2009-08-20 | 2013-02-22 | Yeda Res & Dev | Low frequency glatiramer acetate therapy |
| ITMI20092069A1 (it) | 2009-11-25 | 2011-05-26 | Biofer Spa | Metodo per ottenere una miscela di fattori biologici isolati da colostro e miscela di fattori biologici attivi derivata da colostro. |
| US8759302B2 (en) | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
| CA2814500A1 (en) | 2010-10-11 | 2012-04-19 | Teva Pharmaceutical Industries Ltd | Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate |
| CA2827275A1 (en) | 2011-02-14 | 2012-09-20 | Usv Limited | Copolymer-1, process for preparation and analytical methods thereof |
| US8575198B1 (en) * | 2011-09-07 | 2013-11-05 | Momenta Pharmaceuticals, Inc. | In-process control for the manufacture of glatiramer acetate |
| HK1200274A1 (en) | 2011-10-10 | 2015-08-07 | Teva Pharmaceutical Industries Ltd. | Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate |
| WO2014008400A2 (en) * | 2012-07-06 | 2014-01-09 | 3-D Matrix, Inc. | Fill-finish process for peptide solutions |
| HK1213830A1 (zh) | 2012-10-10 | 2016-07-15 | Teva Pharmaceutical Industries Ltd. | 用於预测醋酸格拉替雷临床反应的生物标志物 |
| MX2015008754A (es) | 2013-01-04 | 2016-04-11 | Teva Pharma | Caracterizacion de un medicamento relacionado con acetato de glatiramer. |
| WO2014128079A1 (en) | 2013-02-19 | 2014-08-28 | Synthon B.V. | Glatiramer acetate multidose formulation |
| US20140271630A1 (en) | 2013-03-12 | 2014-09-18 | Teva Pharmaceutical Industries, Ltd. | Rituximab induction therapy followed by glatiramer acetate therapy |
| CN103169670B (zh) * | 2013-03-22 | 2016-07-06 | 深圳翰宇药业股份有限公司 | 一种醋酸格拉替雷微球及其制备方法 |
| UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
-
2015
- 2015-01-28 US US14/608,126 patent/US9155775B1/en active Active
- 2015-09-21 KR KR1020167028604A patent/KR101737295B1/ko active Active
- 2015-09-21 EP EP15880609.1A patent/EP3113785A4/en not_active Withdrawn
- 2015-09-21 EA EA201691790A patent/EA028484B1/ru unknown
- 2015-09-21 KR KR1020177012458A patent/KR102268210B1/ko active Active
- 2015-09-21 CA CA2945537A patent/CA2945537C/en active Active
- 2015-09-21 UA UAA201610444A patent/UA116060C2/uk unknown
- 2015-09-21 RU RU2017104222A patent/RU2669769C2/ru active
- 2015-09-21 JP JP2017534813A patent/JP2018503627A/ja not_active Withdrawn
- 2015-09-21 BR BR112016023736A patent/BR112016023736A2/pt not_active Application Discontinuation
- 2015-09-21 US US14/860,053 patent/US9763993B2/en active Active
- 2015-09-21 CN CN201580071551.XA patent/CN107530394B/zh active Active
- 2015-09-21 MX MX2016011219A patent/MX352734B/es active IP Right Grant
- 2015-09-21 PE PE2016001955A patent/PE20170296A1/es unknown
- 2015-09-21 AU AU2015380381A patent/AU2015380381B2/en not_active Ceased
- 2015-09-21 WO PCT/US2015/051203 patent/WO2016122722A1/en not_active Ceased
- 2015-09-21 CA CA2965890A patent/CA2965890A1/en not_active Abandoned
- 2015-09-21 US US15/510,156 patent/US20170312331A1/en not_active Abandoned
- 2015-09-24 ES ES15186721.5T patent/ES2584190T3/es active Active
- 2015-09-24 ME MEP-2017-103A patent/ME02721B/me unknown
- 2015-09-24 EP EP17162112.1A patent/EP3238706A1/en not_active Withdrawn
- 2015-09-24 DK DK15186721.5T patent/DK3050556T3/en active
- 2015-09-24 SM SM20170227T patent/SMT201700227T1/it unknown
- 2015-09-24 HU HUE15186721A patent/HUE034059T2/en unknown
- 2015-09-24 LT LTEP15186721.5T patent/LT3050556T/lt unknown
- 2015-09-24 SI SI201530058A patent/SI3050556T1/sl unknown
- 2015-09-24 RS RS20170439A patent/RS55959B1/sr unknown
- 2015-09-24 PT PT151867215T patent/PT3050556T/pt unknown
- 2015-09-24 PL PL15186721T patent/PL3050556T3/pl unknown
- 2015-09-24 EP EP15186721.5A patent/EP3050556B1/en not_active Revoked
- 2015-09-25 EA EA201500881A patent/EA028811B1/ru unknown
- 2015-09-25 EA EA201791555A patent/EA201791555A3/ru unknown
- 2015-09-25 AR ARP150103103A patent/AR102096A1/es not_active Application Discontinuation
-
2016
- 2016-08-16 AU AU2016101453A patent/AU2016101453B4/en not_active Expired
- 2016-09-15 IL IL247851A patent/IL247851A0/en unknown
- 2016-10-07 ZA ZA2016/06903A patent/ZA201606903B/en unknown
- 2016-10-13 CL CL2016002607A patent/CL2016002607A1/es unknown
- 2016-12-14 AU AU2016273881A patent/AU2016273881A1/en not_active Abandoned
-
2017
- 2017-03-28 US US15/471,765 patent/US20170196930A1/en not_active Abandoned
- 2017-04-13 CY CY20171100442T patent/CY1118826T1/el unknown
- 2017-04-21 HR HRP20170625TT patent/HRP20170625T1/hr unknown
- 2017-09-18 US US15/707,378 patent/US20180000884A1/en not_active Abandoned
- 2017-10-19 US US15/788,698 patent/US20180036363A1/en not_active Abandoned
-
2018
- 2018-01-23 AU AU2018200518A patent/AU2018200518A1/en not_active Abandoned
- 2018-07-17 JP JP2018134124A patent/JP6592150B2/ja active Active
-
2019
- 2019-06-06 IL IL267152A patent/IL267152A/en unknown
-
2020
- 2020-09-24 IL IL277601A patent/IL277601B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2016002607A1 (es) | Procedimiento para preparar una preparación farmacéutica de acetato de glatiramer y manitol en un contenedor adecuado que comprende las etapas de obtener una solución acuosa de acetato de glatiramer y manitol, filtración de la solución entre 0 y 17,5 grado celsius y llenado del contenedor. pct | |
| CL2017000984A1 (es) | Reducción de la viscosidad de formulaciones farmacéuticas | |
| CL2016001918A1 (es) | Heteroaril amidas como inhibidores de agregación de proteína | |
| MX379193B (es) | Composiciones en solucion solida y su uso en inflamacion cronica. | |
| PE20181095A1 (es) | Envase blister | |
| ITUA20161349A1 (it) | Capsula migliorata per la preparazione di bevande ad infusione e solubili | |
| IL285440A (en) | Oral compositions containing octreotide in combination with other therapeutic agents for tretment of acromegaly | |
| CL2015002546A1 (es) | Derivados 3-fenilpropilamina sustituidos para el tratamiento de enfermedades y trastornos oftálmicos | |
| MX372956B (es) | Novedosas cepas de lactobacillus y los usos de las mismas. | |
| CL2015001446A1 (es) | Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido. | |
| MX389178B (es) | Formulacion de proporcion fija de insulina glargina/lixisenatida. | |
| BR112015030268A2 (pt) | composição farmacêutica, recipiente, kit, e, método para a preparação de uma composição | |
| BR112016022394A2 (pt) | Composição farmaceuticamente aceitável, composição na forma de uma solução injetável farmaceuticamente aceitável, uso da composição, e, método para a preparação da composição injetável farmaceuticamente aceitável | |
| CL2018001104A1 (es) | Composición para el cuidado de la piel y procedimiento asociado. | |
| MX2017000676A (es) | Oritavancina de alta pureza y metodo para producir la misma. | |
| AR106559A1 (es) | Suspensión acuosa para administración oral y método para su preparación | |
| HUE057871T2 (hu) | Gyógyászati hatóanyagokat tartalmazó hialuronán konjugátumok, eljárások és kompozíciók | |
| EP3630800A4 (en) | VACCINE AGAINST NECROTIC ENTERITIS IN POULTRY | |
| ITUA20161354A1 (it) | Capsula per la preparazione di bevande ad infusione e solubili | |
| LT3217998T (lt) | Kompozicijos, turinčios apoekvorino, skirtos naudoti neuroninių ląstelių žūties nuo išemijos gydymo būde, įvedant jas peroraliai | |
| SMT202100175T1 (it) | Composizione atta a preservare lo stato fisiologico di pelle e cappelli ed a ristabilire le loro funzioni rigenerative | |
| CL2019002283A1 (es) | Composición líquida que contiene pradofloxacina. | |
| EP3632816A4 (en) | FOOD PRODUCT READY TO USE IN VACUUM PACKAGING | |
| RU2014140385A (ru) | Композиция для повышения адаптации организма человека в высокогорье | |
| UA92408U (ru) | Крем для применения при синдроме диабетической стопы у больных сахарным диабетом |